ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

September 26, 2024

Study Completion Date

September 26, 2024

Conditions
Advanced Non Small Cell Lung Cancer
Interventions
BIOLOGICAL

ATL001

ATL001 infusion

DRUG

Pembrolizumab

Checkpoint inhibitor

Trial Locations (19)

10017

Memorial Sloan Kettering Cancer Center, New York

28040

Instituto de Investigación Sanitaria Fundación Jimenez Díaz, Madrid

28050

Centro Integral Oncologico Clara Campal Hospital Universitario HM Sanchinarro, Madrid

33612

Moffitt Cancer Center, Tampa

45147

Universitätsklinikum Essen, Essen

46010

Hospital Clinico Universitario de Valencia, Valencia

69310

Centre Hospitalier Lyon Sud, Pierre-Bénite

06510

Yale University School of Medicine, New Haven

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

08036

Hospital Clinic de Barcelona, Barcelona

B15 2GW

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham

Unknown

Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne

University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton

LS9 7TF

The Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds

NW1 2PG

University College London Hospitals (UCLH) NHS Foundation Trust, University College Hospital, London

SE19RT

Guys and St Thomas' NHS Foundation Trust, Guy's Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Christie Hospital, Manchester

M23 9LT

Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester

All Listed Sponsors
lead

Achilles Therapeutics UK Limited

INDUSTRY

NCT04032847 - ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | Biotech Hunter | Biotech Hunter